The Northwestern University Cancer Health Equity Research SPORE (NU-CHERS)

西北大学癌症健康公平研究 SPORE (NU-CHERS)

• 批准号: 10265425
• 负责人: MELISSA A. SIMON
• 金额: $ 102.31万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-17 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10265425
• 关键词: Accounting; Award; Bioinformatics; Biological; Biological Markers; Biometry; Blood; Cancer Research Project; Chicago; Cities; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collection; Communication; Communities; Complement; Comprehensive Cancer Center; County; DNA; DNA Methylation; Development; Discipline of obstetrics; Disease Progression; Early Diagnosis; Endometrial Carcinoma; Endometrial Neoplasms; Epigenetic Process; Evaluation; Event; Expression Profiling; Fostering; Foundations; Funding; Future; Galanin; Genes; Genomics; Goals; Gynecologic; Gynecologic Oncology; Gynecology; Hospitals; In Vitro; Incidence; Individual; Infrastructure; Intervention; Lead; Leadership; Link; Location; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of ovary; Measures; Minority; Minority Groups; Minority Recruitment; Modeling; Molecular; Molecular and Cellular Biology; Morbidity - disease rate; Organoids; Outcome; Participant; Pathology; Pathway interactions; Pattern; Pilot Projects; Platinum; Prevention; Process; Public Hospitals; Research; Research Personnel; Research Project Grants; Resistance; Resources; Science; Seeds; Serous; Solid; Tissues; Translational Research; United States; United States National Institutes of Health; Universities; Vision; Woman; Work; anticancer research; base; biobank; black women; cancer health disparity; cancer therapy; cancer type; career development; comparative; cooking; design; ethnic minority population; exome sequencing; experience; health disparity; health equity; improved; in vivo; infrastructure development; innovation; insight; lens; methylome; methylomics; mortality; mutational status; novel; novel marker; outreach; patient derived xenograft model; precision medicine; programs; racial and ethnic; racial difference; racial disparity; repository; response; transcriptome sequencing; translational cancer research; translational pipeline; translational research program; translational scientist; treatment response; tumor

ABSTRACT Centered in Chicago, one of the most diverse yet segregated cities with some of the most striking health disparities in the US, this P20 feasibility and planning proposal to develop the Northwestern University Cancer Health Equity Research SPORE (NU-CHERS) will generate scientific findings and establish sustainable, collaborative, academic and community infrastructure that will serve as the foundation for a comprehensive translational cancer research program focused on gynecologic cancer health disparities. In this proposal, we set our initial translational research focus on endometrial and ovarian cancer disparities as experienced by Black women. This NU-CHERS P20 program leverages outstanding translational research capacity at Northwestern University and its NCI-designated Robert H. Lurie Comprehensive Cancer Center. Research Project 1 investigates racial disparities in endometrial cancer through tumor genomics. Findings will generate critical information that not only deepens our understanding of the biological racial differences in endometrial tumors but can be used as a predictive measure for racial differences in response to treatments. Research Project 2 focuses on racial differences in DNA methylation events in ovarian cancer which may impact response to platinum-based ovarian cancer treatment and explain the striking disparity in survival experienced by Black women. The study will define the methylomes of high-grade serous ovarian cancer in Black and White women as well as develop high-grade serous ovarian cancer-derived patient derived xenografts (PDX) and organoids from which response of these models to platinum will be assessed in vitro and in vivo. Findings will define pathways and genes regulated epigenetically, which could account for disparity in clinical outcomes and may become relevant targets for intervention. To support these projects and build a solid infrastructure for a future funded gynecologic cancer health disparities P50 SPORE, we propose two Cores. The Administrative Core (AC) is the focal point for scientific, fiscal and administrative oversight and integration. The Gynecologic Biospecimen Pathology Core (GBPC) will maintain tissue/blood repositories for current and future NU-CHERS projects, in partnership with the John H. Stroger, Jr. Hospital of Cook County to enhance the availability of minority gynecologic biospecimens available to NU-CHERS researchers. In addition, we propose a Developmental Research Program (DRP) to support NU-CHERS infrastructure development goals and pipeline of translational research excellence. The NU-CHERS P20 team is comprised of basic, translational, and clinical investigators with synergistic strengths poised to forge a lasting translational research program focused on understanding and reducing gynecologic cancer disparities.

摘要 以芝加哥为中心，这是一个最多样化但种族隔离的城市， 在美国的差距，这P20的可行性和规划建议，以发展西北大学癌症 健康公平研究孢子（NU-CHERS）将产生科学发现，并建立可持续的， 协作，学术和社区基础设施，将作为一个全面的基础 转化癌症研究计划，重点是妇科癌症的健康差距。在本提案中，我们设定 我们最初的转化研究集中在子宫内膜癌和卵巢癌的差异，如布莱克所经历的， 妇女该NU-CHERS P20计划利用西北大学杰出的转化研究能力 大学和它的NCI指定的罗伯特H。卢里综合癌症中心。研究项目1 通过肿瘤基因组学研究子宫内膜癌的种族差异。调查结果将产生关键的 这些信息不仅加深了我们对子宫内膜肿瘤生物学种族差异的理解， 但可用作对治疗反应的种族差异的预测测量。研究项目2 关注卵巢癌中DNA甲基化事件的种族差异，这可能影响对 铂为基础的卵巢癌治疗，并解释生存的显着差异经历的黑色 妇女这项研究将确定黑人和白色妇女中高级别浆液性卵巢癌的甲基化组 以及开发高级别浆液性卵巢癌患者来源的异种移植物（PDX）和类器官 由此将在体外和体内评估这些模型对铂的反应。调查结果将确定 表观遗传学调节的途径和基因，这可能解释临床结果的差异， 成为相关的干预目标。为了支持这些项目并为未来建立坚实的基础设施， 资助妇科癌症健康差距P50孢子，我们提出了两个核心。行政核心（AC） 是科学、财政和行政监督和一体化的协调中心。妇科生物标本 病理学核心（GBPC）将为当前和未来的NU-CHERS项目维护组织/血液储存库， 与约翰·H。小斯特罗格库克县医院，以提高少数民族的可用性 妇科生物标本提供给NU-CHERS研究人员。此外，我们还提出了一个发展 研究计划（DRP），以支持NU-CHERS基础设施的发展目标和管道的转化 卓越的研究NU-CHERS P20团队由基础、翻译和临床研究人员组成 协同优势准备建立一个持久的翻译研究计划，重点是理解和 减少妇科癌症的差异。